Dryden, Matthew <br/><br/>
A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities.  [electronic resource] 

 -  The Journal of antimicrobial chemotherapy  12 2016 
 - 3575-3584 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1460-2091 
<br/><br/><label>Standard No.: </label>10.1093/jac/dkw333  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Intravenous<br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Anti-Bacterial Agents--administration & dosage<br/>Aztreonam--administration & dosage<br/>Cephalosporins--administration & dosage<br/>Double-Blind Method<br/>Drug-Related Side Effects and Adverse Reactions--epidemiology<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Prospective Studies<br/>Skin Diseases, Bacterial--complications<br/>Soft Tissue Infections--complications<br/>Systemic Inflammatory Response Syndrome--drug therapy<br/>Treatment Outcome<br/>Vancomycin--administration & dosage<br/>Young Adult<br/>Ceftaroline